Literature DB >> 10549493

Focal fractionated conformal stereotactic boost following conventional radiotherapy of high-grade gliomas: a randomized phase III study. A joint study of the EORTC (22972) and the MRC (BR10).

M Brada1, B Baumert.   

Abstract

Entities:  

Mesh：

Year:  1999        PMID： 10549493     DOI： 10.1159/000061233

Source DB:  PubMed          Journal:  Front Radiat Ther Oncol        ISSN： 0071-9676


× No keyword cloud information.
  5 in total

1.  Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.

Authors:  Mario Balducci; Silvia Chiesa; Barbara Diletto; Giuseppe Roberto D'Agostino; Annunziato Mangiola; Stefania Manfrida; Giovanna Mantini; Alessio Albanese; Alba Fiorentino; Vincenzo Frascino; Berardino De Bari; Francesco Micciche'; Fiorenza De Rose; Alessio Giuseppe Morganti; Carmelo Anile; Vincenzo Valentini
Journal:  Neuro Oncol       Date:  2011-10-12       Impact factor: 12.300

2.  Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy.

Authors:  Patrick Beauchesne; Valerie Bernier; Charlotte Carnin; Luc Taillandier; Mohamed Djabri; Laurent Martin; Xavier Michel; Jean-Philippe Maire; Toufic Khalil; Christine Kerr; Thierry Gorlia; Roger Stupp; Remy Pedeux
Journal:  Neuro Oncol       Date:  2010-02-11       Impact factor: 12.300

3.  Combined salvage therapies for recurrent glioblastoma multiforme: evaluation of an interdisciplinary treatment algorithm.

Authors:  Eleftherios Archavlis; Nikolaos Tselis; Gerhard Birn; Peter Ulrich; Nikolaos Zamboglou
Journal:  J Neurooncol       Date:  2014-06-20       Impact factor: 4.130

4.  Three-dimensional conformal radiotherapy for astrocytic tumors involving the eloquent area in children and young adults.

Authors:  Taiga Nishihori; Hiroki Shirato; Hidefumi Aoyama; Rikiya Onimaru; Takashi Komae; Nobuaki Ishii; Jun Ikeda; Kazuo Miyasaka; Yutaka Sawamura; Yoshinobu Iwasaki
Journal:  J Neurooncol       Date:  2002-11       Impact factor: 4.130

5.  ProBDNF and its receptors are upregulated in glioma and inhibit the growth of glioma cells in vitro.

Authors:  Jing Xiong; Li Zhou; Miao Yang; Yoon Lim; Yu-hong Zhu; Deng-li Fu; Zhi-wei Li; Jin-hua Zhong; Zhi-cheng Xiao; Xin-Fu Zhou
Journal:  Neuro Oncol       Date:  2013-04-10       Impact factor: 12.300
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.